Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer

NCT01846091 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01846091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01846091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
April 9, 2013
Completion date
November 26, 2019
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, estrogen receptor positive, head and neck squamous cell carcinoma, her2/neu negative, her2/neu positive, invasive breast carcinoma, progesterone receptor negative, progesterone receptor positive, recurrent head and neck carcinoma, stage iv breast cancer, triple-negative breast carcinoma